Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

DBV Technologies S.A. (DBVT) vs Pharming Group N.V. Sponsored ADR (PHAR)

DBV Technologies S.A. and Pharming Group N.V. Sponsored ADR are both Biotechnology companies. DBV Technologies S.A. and Pharming Group N.V. Sponsored ADR are of similar size ($738.9M and $734.7M). DBV Technologies S.A. has negative trailing earnings, so its P/E is not meaningful; Pharming Group N.V. Sponsored ADR trades at 69.7×. DBV Technologies S.A. grew revenue faster over the last twelve months: 27.1% against 7.85%. Pharming Group N.V. Sponsored ADR has the higher net margin (2.55% vs −3,564.6%) and the higher return on invested capital (5.50% vs 0.00%). Across the 19 metrics below, Pharming Group N.V. Sponsored ADR leads on 14 and DBV Technologies S.A. on 5.

Valuation

Metric DBVT PHAR Biotechnology median
P/E n/m 69.73 7.88
P/S 203.07 1.52 11.47
P/B 6.25 2.06 2.52
Price to free cash flow n/m 16.24 21.16
EV/EBITDA n/m 16.28 0.74
EV/Sales 167.65 1.36 10.73
Earnings yield (30.36%) 1.43% (28.84%)
Free cash flow yield (17.02%) 6.16% (23.03%)

Profitability

Metric DBVT PHAR Biotechnology median
Gross margin 100.00% 86.54% 65.16%
Operating margin (3,601.22%) 5.04% 0.00%
Net margin (3,564.57%) 2.55% 0.00%
Free cash flow margin (3,456.50%) 9.38% 0.00%
Return on equity (142.63%) 3.67% (57.72%)
Return on assets (95.98%) 2.05% (49.22%)
Return on invested capital 0.00% 5.50% 0.00%

Growth

Metric DBVT PHAR Biotechnology median
Revenue growth (TTM) 27.12% 7.85% 5.64%
EPS growth (last fiscal year) 10.26% 125.00% —
Revenue growth, 5-year CAGR (12.95%) 12.13% 8.40%
Net income growth, 5-year CAGR 0.00% (40.35%) 0.00%

Health

Metric DBVT PHAR Biotechnology median
Debt to equity 0.00 0.36 0.00
Current ratio 3.72 3.01 4.73
Net debt to EBITDA 1.35 (2.21) 0.96

Dividend

Metric DBVT PHAR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DBVT PHAR Biotechnology median
Market cap 734.72m 738.94m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack